Zoetis stock rises after FDA conditionally approves screwworm drug
PositiveFinancial Markets

Zoetis has seen a significant rise in its stock value following the FDA's conditional approval of its new screwworm drug. This approval is a major milestone for the company, as it opens up new avenues for addressing a critical agricultural pest that affects livestock. The positive market reaction reflects investor confidence in Zoetis's innovative approach to animal health, which could lead to increased sales and a stronger position in the pharmaceutical industry.
— Curated by the World Pulse Now AI Editorial System